ES2725805T3 - Un conjugado de GLP-2 de sitio específico que usa un fragmento de inmunoglobulia - Google Patents

Un conjugado de GLP-2 de sitio específico que usa un fragmento de inmunoglobulia Download PDF

Info

Publication number
ES2725805T3
ES2725805T3 ES12861579T ES12861579T ES2725805T3 ES 2725805 T3 ES2725805 T3 ES 2725805T3 ES 12861579 T ES12861579 T ES 12861579T ES 12861579 T ES12861579 T ES 12861579T ES 2725805 T3 ES2725805 T3 ES 2725805T3
Authority
ES
Spain
Prior art keywords
glp
group
derivative
fragment
peptidyl polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12861579T
Other languages
English (en)
Spanish (es)
Inventor
Seung Su Kim
Se Young Lim
Sung Youb Jung
Se Chang Kwon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Science Co Ltd
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Application granted granted Critical
Publication of ES2725805T3 publication Critical patent/ES2725805T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES12861579T 2011-12-30 2012-12-28 Un conjugado de GLP-2 de sitio específico que usa un fragmento de inmunoglobulia Active ES2725805T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110147684A KR101895047B1 (ko) 2011-12-30 2011-12-30 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
PCT/KR2012/011748 WO2013100704A1 (en) 2011-12-30 2012-12-28 A site-specific glp-2 conjugate using an immunoglobulin fragment

Publications (1)

Publication Number Publication Date
ES2725805T3 true ES2725805T3 (es) 2019-09-27

Family

ID=48698036

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12861579T Active ES2725805T3 (es) 2011-12-30 2012-12-28 Un conjugado de GLP-2 de sitio específico que usa un fragmento de inmunoglobulia

Country Status (9)

Country Link
US (1) US9504757B2 (cg-RX-API-DMAC7.html)
EP (1) EP2797621B1 (cg-RX-API-DMAC7.html)
JP (1) JP6131490B2 (cg-RX-API-DMAC7.html)
KR (1) KR101895047B1 (cg-RX-API-DMAC7.html)
CN (2) CN109810198B (cg-RX-API-DMAC7.html)
AR (1) AR089506A1 (cg-RX-API-DMAC7.html)
ES (1) ES2725805T3 (cg-RX-API-DMAC7.html)
TW (1) TWI666219B (cg-RX-API-DMAC7.html)
WO (1) WO2013100704A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
US9949927B2 (en) 2012-04-10 2018-04-24 The Regents Of The University Of California Bis-polymer lipid-peptide conjugates and nanoparticles thereof
EP3046586B1 (en) * 2013-09-19 2021-07-07 The Regents of The University of California Methods of treatment using bis-polymer lipid-peptide conjugates and nanoparticles thereof
US9994616B2 (en) 2013-10-15 2018-06-12 The University Of Tokyo c-Met protein agonist
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
KR102385120B1 (ko) * 2014-03-31 2022-04-12 한미약품 주식회사 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
EP4303228B1 (en) 2016-07-11 2026-05-27 OPKO Biologics Ltd. Long-acting coagulation factor vii and methods of producing same
CN107987170B (zh) * 2016-10-27 2018-12-18 浙江道尔生物科技有限公司 一种用于治疗肠道疾病的融合蛋白
WO2018157131A1 (en) 2017-02-27 2018-08-30 Urigen N.A. Treatment of lower urinary tract epithelium with glucagon like peptide 2
KR102174436B1 (ko) * 2017-08-17 2020-11-04 주식회사 엘지화학 불용성 안료 화합물의 정성분석방법
AU2018321841A1 (en) * 2017-08-22 2020-02-20 Shire-Nps Pharmaceuticals, Inc. GLP-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
AR113258A1 (es) * 2017-09-28 2020-03-11 Hanmi Pharm Ind Co Ltd Conjugados persistentes de derivados del péptido 2 similar al glucagón (glp-2)
CN111629745A (zh) * 2017-11-06 2020-09-04 夏尔-Nps医药品有限公司 用于在手术前、期间或之后投与的glp-2类似物和肽体(peptibodies)
WO2020086741A1 (en) * 2018-10-24 2020-04-30 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
US20200254065A1 (en) * 2019-02-11 2020-08-13 Opko Biologics Ltd. Long-acting glp-2 analogs
WO2020198604A1 (en) * 2019-03-28 2020-10-01 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods of treating and preventing systemic complications of acute illness
EP4069726A4 (en) 2019-12-04 2024-03-20 The Scripps Research Institute GLP2 RECEPTOR AGONISTS AND METHOD OF USE
EP4082561A4 (en) * 2019-12-24 2024-02-07 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating metabolic bone diseases, comprising glp-2 or conjugate thereof
CN115697375A (zh) * 2020-04-03 2023-02-03 韩美药品株式会社 预防或治疗放疗、化疗或其组合引发的粘膜炎的包含glp-2衍生物或其长效缀合物的药物组合物
IL298298A (en) * 2020-05-22 2023-01-01 Hanmi Pharm Ind Co Ltd A liquid formulation of a long-acting conjugate of glp–2
CN111560062A (zh) * 2020-05-26 2020-08-21 成都圣诺生物制药有限公司 一种Elisiglutide的制备方法
WO2022159555A1 (en) * 2021-01-20 2022-07-28 The Trustees Of Columbia University In The City Of New York Methods for treating graft-versus-host disease using glp-2 agonists and analogues thereof
AU2022289610A1 (en) 2021-06-09 2024-01-25 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
DK1360202T3 (da) * 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
CN1705681A (zh) * 2002-10-14 2005-12-07 诺沃挪第克公司 Glp-2化合物、制剂及其用途
US20070060512A1 (en) 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
US7829307B2 (en) 2003-11-21 2010-11-09 Nps Pharmaceuticals, Inc. Production of glucagon-like peptide 2
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
DE602006020123D1 (de) 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
AU2006321743A1 (en) 2005-10-24 2007-06-14 Centocor, Inc. GLP-2 mimetibodies, polypeptides, compositions, methods and uses
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP5759976B2 (ja) * 2009-03-20 2015-08-05 ハンミ・サイエンス・カンパニー・リミテッド 位置特異的な生理活性ポリペプチド結合体の調製方法
JP2012521197A (ja) * 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
KR101746686B1 (ko) 2010-10-26 2017-06-15 한미사이언스 주식회사 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―2(glp―2)약물 결합체

Also Published As

Publication number Publication date
CN104144697A (zh) 2014-11-12
KR20130078634A (ko) 2013-07-10
US20140377290A1 (en) 2014-12-25
CN109810198A (zh) 2019-05-28
EP2797621B1 (en) 2019-03-06
JP2015503554A (ja) 2015-02-02
EP2797621A4 (en) 2015-09-02
EP2797621A1 (en) 2014-11-05
TW201333032A (zh) 2013-08-16
WO2013100704A1 (en) 2013-07-04
KR101895047B1 (ko) 2018-09-06
TWI666219B (zh) 2019-07-21
AR089506A1 (es) 2014-08-27
JP6131490B2 (ja) 2017-05-24
US9504757B2 (en) 2016-11-29
CN109810198B (zh) 2023-06-06

Similar Documents

Publication Publication Date Title
EP2797621B1 (en) A site-specific glp-2 conjugate using an immunoglobulin fragment
ES2802099T3 (es) Una composición para el tratamiento de la diabetes que comprende un análogo de oxintomodulina
ES2942187T3 (es) Composición para tratar la hiperlipidemia que comprende un derivado de oxintomodulina
EP2552474B1 (en) An insulin conjugate using an immunoglobulin fragment
US9072794B2 (en) Long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
ES2897732T3 (es) Composición para tratar la diabetes mellitus que comprende insulina y un agonista doble de glp-1/glucagón
ES2748158T3 (es) Formulación líquida de conjugado de proteínas que comprende la oxintomodulina y un fragmento de inmunoglobulina
ES2674581T3 (es) Análogo de exendina-4 pegilado con polietilenglicol o derivado del mismo, método de preparación del mismo y composición farmacéutica para evitar o tratar diabetes, que contiene el mismo como principio activo
TWI658835B (zh) 用於預防或治療非酒精性脂肪肝疾病之醫藥組合物
ES2898718T3 (es) Método para preparar un complejo polipeptídico fisiológicamente activo
ES2738676T3 (es) Conjugado de insulina específico de sitio
ES2897935T3 (es) Método para mejorar la solubilidad de proteína y péptido mediante el uso del enlace a un fragmento Fc de inmunoglobulina
TW201201831A (en) Long-acting interferon beta formulation using immunoglobulin fragment
BR112020006189A2 (pt) conjugado de peptídeo-2 tipo glucagon (glp-2), derivado de glp-2 que compreende uma sequência de aminoácidos e seu método se preparação, ácido nucleico isolado que codifica o derivado de glp-2, vetor de expressão recombinante que compreende o ácido nucleico, transformante que compreende o vetor de expressão recombinante, composição farmacêutica para prevenir ou tratar uma ou mais doenças selecionadas
KR101746686B1 (ko) 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―2(glp―2)약물 결합체
ES2713979T3 (es) Formulación líquida de conjugado de hormona de crecimiento humana altamente concentrada de acción prolongada
US20230159607A1 (en) Pharmaceutical composition for preventing or treating mucositis induced by radiotherapy, chemotherapy, or combination thereof, comprising glp-2 derivatives or long-acting conjugate of same
US20230285584A1 (en) Liquid formulation of long-acting conjugate of glp-2